DKK 1120.0
(-2.61%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | - DKK | 100.0% |
2022 | -782 Thousand DKK | -104.32% |
2021 | 18.08 Million DKK | 447.8% |
2020 | -5.19 Million DKK | -36.74% |
2019 | -3.8 Million DKK | -178.33% |
2018 | -1.36 Million DKK | -83.11% |
2017 | -746 Thousand DKK | -30.42% |
2016 | -572 Thousand DKK | 0.0% |
2015 | - DKK | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | - DKK | 0.0% |
2024 Q2 | - DKK | 0.0% |
2023 Q4 | - DKK | 0.0% |
2023 Q3 | - DKK | 0.0% |
2023 Q1 | - DKK | 100.0% |
2023 Q2 | - DKK | 0.0% |
2023 FY | - DKK | 100.0% |
2022 Q1 | - DKK | -100.0% |
2022 Q4 | -1.82 Million DKK | 0.0% |
2022 FY | -782 Thousand DKK | -104.32% |
2022 Q2 | - DKK | 0.0% |
2021 Q1 | - DKK | 100.0% |
2021 FY | 18.08 Million DKK | 447.8% |
2021 Q3 | - DKK | -100.0% |
2021 Q4 | 23.04 Million DKK | 0.0% |
2021 Q2 | 13.15 Million DKK | 0.0% |
2020 Q1 | - DKK | 100.0% |
2020 FY | -5.19 Million DKK | -36.74% |
2020 Q4 | -2.94 Million DKK | 0.0% |
2020 Q3 | - DKK | 100.0% |
2020 Q2 | -2.25 Million DKK | 0.0% |
2019 Q1 | - DKK | 0.0% |
2019 Q3 | - DKK | 100.0% |
2019 Q2 | -2.06 Million DKK | 0.0% |
2019 Q4 | -1.73 Million DKK | 0.0% |
2019 FY | -3.8 Million DKK | -178.33% |
2018 Q3 | - DKK | 0.0% |
2018 Q4 | - DKK | 0.0% |
2018 Q2 | - DKK | 0.0% |
2018 FY | -1.36 Million DKK | -83.11% |
2018 Q1 | - DKK | 0.0% |
2017 Q2 | - DKK | 0.0% |
2017 Q3 | - DKK | 0.0% |
2017 Q4 | - DKK | 0.0% |
2017 FY | -746 Thousand DKK | -30.42% |
2017 Q1 | - DKK | 0.0% |
2016 Q4 | - DKK | 0.0% |
2016 FY | -572 Thousand DKK | 0.0% |
2016 Q2 | - DKK | 0.0% |
2016 Q1 | - DKK | 0.0% |
2016 Q3 | - DKK | 0.0% |
2015 FY | - DKK | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
ALK-Abelló A/S | 3.03 Billion DKK | 100.0% |
Bavarian Nordic A/S | 4.52 Billion DKK | 100.0% |
Genmab A/S | 16.24 Billion DKK | 100.0% |
Gubra A/S | 114.93 Million DKK | 100.0% |
Novo Nordisk A/S | 196.49 Billion DKK | 100.0% |
Pharma Equity Group A/S | -480 Thousand DKK | 100.0% |
Zealand Pharma A/S | 323.61 Million DKK | 100.0% |